Drug
CG 5503 Tapentadol
CG 5503 Tapentadol: highest development phase Phase 3, developed by Johnson & Johnson. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Johnson & Johnson
Trials
| Drug | Phase | Indication |
|---|---|---|
| CG 5503;tapentadol NCT00364546 | Phase 3 | Osteoarthritis |
Latest
No recent events.
Follow CG 5503 Tapentadol on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.